Diametric Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Diametric Capital’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.8K	Buy	+15,386	New	+$36.6K	0.01%	463

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Diametric Capital's BDTX Position: Q1 2026 in Review

Diametric Capital opened a new position in Black Diamond Therapeutics (BDTX) in Q1 2026: 15,386 shares worth $32.8K. The stake represents 0.01% of the portfolio and ranks #463 among its holdings.

104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Diametric Capital held 15,386 shares of Black Diamond Therapeutics worth $32.8K as of Q1 2026.
Black Diamond Therapeutics was a new Diametric Capital position in Q1 2026.
Black Diamond Therapeutics made up 0.01% of Diametric Capital's portfolio in Q1 2026, its #463 holding.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.